STLN · Starling Oncology, Inc. · Financials
The latest filing states the doubt was alleviated.
“the Company conducted an evaluation as to whether there were conditions and events, considered in the aggregate, which raised substantial doubt as to its ability to continue as a going concern within one year after the date of the issuance of such financial statements. The Company had cash and cash equivalents of $41,094 and an accumulated deficit of $283,700 at June 30, 2026, and a net loss of $12,281 and net cash provided by operations of $9,725 for the six months ended June 30, 2026. The Company has concluded that it will have sufficient liquidity to fund its operations for at least one year from the date these consolidated financial statements are issued.”View the 10-Q filed Aug 6, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|---|
| $650M – $670M | $587.24M | $502.73M | $393.41MG | $324.24MG | $252.48MG | $203M | $187.52M | |
| — | -$7.32M | — | — | -$6.78M | -$4.08M | -$320K | — | |
| — | $4.22M | — | — | — | — | — | $309.17K | |
| — | $111.45M | $105.57M | $107.83M | $113.85M | $119.69M | $83.37M | $41.9M | |
| — | $2.87M | $2.98M | $3.09M | $3.01M | $2.89M | $2.52M | $2.49M | |
| — | $6.81M | $6.94M | $6.29M | $5.87M | $4.41M | $3.34M | $3.18M | |
| — | -$26.09M | -$36.08M | -$60.12M | -$77.02M | -$81.95M | -$45.86M | -$8.2M | |
| — | — | -7.18% | -15.28% | -23.75% | -32.46% | -22.59% | -4.37% | |
| — | -$19.28M | -$29.14M | -$53.83M | -$71.15M | -$77.54M | -$42.52M | -$5.02M | |
| — | $7.63M | $11.28M | $7.5M | $6.78M | — | $320K | $347K | |
| — | $5798 | — | — | — | — | — | $254.15K | |
| — | -$10.2M | -$24.65M | -$4.55M | -$6.09M | $81.86M | $34.26M | -$6.62M | |
| — | -$36.29M | -$60.74M | -$64.66M | -$83.1M | -$91K | -$11.6M | -$14.82M | |
| — | $0 | -$131K | $0 | -$36K | -$243K | -$671K | -$493K | |
| — | -$36.29M | -$60.61M | -$64.66M | -$83.07M | $152K | -$10.93M | -$14.32M | |
| — | — | -12.06% | -16.44% | -25.62% | 0.06% | -5.38% | -7.64% | |
| — | -$30.57M | -$50.31M | -$53.01M | -$67.88M | $68K | -$10.63M | — | |
| USD/shares | — | -$0.28 | -$0.54 | -$0.71 | -$0.92 | $0.00 | -$0.16 | -$0.24 |
| USD/shares | — | -$0.28 | -$0.54 | -$0.71 | -$0.92 | -$0.21 | -$0.16 | -$0.24 |
| shares | — | — | 92.39M | 75.04M | 73.75M | 72.79M | 66.23M | 59.12M |
| shares | — | — | 92.39M | 75.04M | 73.75M | 80.61M | 66.23M | 59.12M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2024: $10.02M in buybacks.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Finance lease liabilities | 2026-06-30 | USD 47,000 | 10-Q filed 2026-08-06 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Noncurrent debt carrying amount | 2026-06-30 | USD 79,867,000 | 10-Q filed 2026-08-06 |
| Operating lease liabilities | 2026-06-30 | USD 24,609,000 | 10-Q filed 2026-08-06 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 32 similar-size Medical Care Facilities companies (of 56 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Specialty Pharmacy Segment | $269,176,000 | $179,916,000 | — | — | — | — |
| Patient Services Segment | $228,991,000 | $204,883,000 | $213,504,000 | $166,785,000 | $124,074,000 | $116,817,000 |
| Clinical Trials and Other Segment | $4,562,000 | $8,613,000 | $6,900,000 | $6,355,000 | $6,379,000 | $6,808,000 |
| Dispensary Segment | — | — | $103,835,000 | $79,343,000 | $72,550,000 | $63,890,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Health Care Specialty Pharmacy | $269,176,000 | $179,916,000 | — | — | — | — |
| Fee for Service | $148,510,000 | $136,197,000 | $143,134,000 | $105,444,000 | $69,789,000 | $79,436,000 |
| Capitated Revenue | $80,481,000 | $68,686,000 | $70,370,000 | $61,341,000 | $54,285,000 | $37,381,000 |
| Clinical Research Trials and Other Revenue | $4,562,000 | $8,613,000 | $6,900,000 | $6,355,000 | $6,379,000 | $6,808,000 |
| Dispensary Revenue | — | $179,916,000 | $103,835,000 | $79,343,000 | $72,550,000 | $63,890,000 |